Fundamento racional para el tratamiento precoz de la esclerosis multiple

Translated title of the contribution: Rational for an early treatment of multiple sclerosis

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of unknown etiology. Its pathological hallmark is the presence within the CNS of inflammatory infiltrates containing few autoreactive T cells and a multitude of pathogenic nonspecific lymphocytes. Based on that, various non-specific immunosuppressive agents have been tested with marginal benefits on the natural evolution of the disease and frequent short- and long-term adverse effects. Moreover, due to their unfavourable profile, these therapies have been usually limited to patients with progressive courses or high clinical activity. The recent approval of IFNβ and Copolymer 1, as therapies able to modify the disease course in relapsing-remitting and secondary progressive, as well as the available immunopathological and clinical data suggesting that the early treatment of MS with safe profile immunomodulatory drugs could be advantageous compared to late treatments, supports the 'putative' relevance of these new drugs in the early treatment of MS patients. However we must wait for the results of ongoing clinical trials to define if such an early treatment has substantial advantages compared to late treatment.

Original languageSpanish
Pages (from-to)1265-1268
Number of pages4
JournalRevista de Neurologia
Volume30
Issue number12
Publication statusPublished - Jun 16 2000

Fingerprint

Multiple Sclerosis
Therapeutics
Central Nervous System
Demyelinating Diseases
Immunosuppressive Agents
Pharmaceutical Preparations
Clinical Trials
Lymphocytes
T-Lymphocytes

Keywords

  • Copolymer 1
  • Early treatment
  • IFNβ
  • Immunomodulatory drugs
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Fundamento racional para el tratamiento precoz de la esclerosis multiple. / Comi, G.; Martino, G.

In: Revista de Neurologia, Vol. 30, No. 12, 16.06.2000, p. 1265-1268.

Research output: Contribution to journalArticle

@article{4486d279c90445c3a8246176694531fc,
title = "Fundamento racional para el tratamiento precoz de la esclerosis multiple",
abstract = "Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of unknown etiology. Its pathological hallmark is the presence within the CNS of inflammatory infiltrates containing few autoreactive T cells and a multitude of pathogenic nonspecific lymphocytes. Based on that, various non-specific immunosuppressive agents have been tested with marginal benefits on the natural evolution of the disease and frequent short- and long-term adverse effects. Moreover, due to their unfavourable profile, these therapies have been usually limited to patients with progressive courses or high clinical activity. The recent approval of IFNβ and Copolymer 1, as therapies able to modify the disease course in relapsing-remitting and secondary progressive, as well as the available immunopathological and clinical data suggesting that the early treatment of MS with safe profile immunomodulatory drugs could be advantageous compared to late treatments, supports the 'putative' relevance of these new drugs in the early treatment of MS patients. However we must wait for the results of ongoing clinical trials to define if such an early treatment has substantial advantages compared to late treatment.",
keywords = "Copolymer 1, Early treatment, IFNβ, Immunomodulatory drugs, Multiple sclerosis",
author = "G. Comi and G. Martino",
year = "2000",
month = "6",
day = "16",
language = "Spagnolo",
volume = "30",
pages = "1265--1268",
journal = "Revista de Neurologia",
issn = "0210-0010",
publisher = "Revista de Neurologia",
number = "12",

}

TY - JOUR

T1 - Fundamento racional para el tratamiento precoz de la esclerosis multiple

AU - Comi, G.

AU - Martino, G.

PY - 2000/6/16

Y1 - 2000/6/16

N2 - Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of unknown etiology. Its pathological hallmark is the presence within the CNS of inflammatory infiltrates containing few autoreactive T cells and a multitude of pathogenic nonspecific lymphocytes. Based on that, various non-specific immunosuppressive agents have been tested with marginal benefits on the natural evolution of the disease and frequent short- and long-term adverse effects. Moreover, due to their unfavourable profile, these therapies have been usually limited to patients with progressive courses or high clinical activity. The recent approval of IFNβ and Copolymer 1, as therapies able to modify the disease course in relapsing-remitting and secondary progressive, as well as the available immunopathological and clinical data suggesting that the early treatment of MS with safe profile immunomodulatory drugs could be advantageous compared to late treatments, supports the 'putative' relevance of these new drugs in the early treatment of MS patients. However we must wait for the results of ongoing clinical trials to define if such an early treatment has substantial advantages compared to late treatment.

AB - Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of unknown etiology. Its pathological hallmark is the presence within the CNS of inflammatory infiltrates containing few autoreactive T cells and a multitude of pathogenic nonspecific lymphocytes. Based on that, various non-specific immunosuppressive agents have been tested with marginal benefits on the natural evolution of the disease and frequent short- and long-term adverse effects. Moreover, due to their unfavourable profile, these therapies have been usually limited to patients with progressive courses or high clinical activity. The recent approval of IFNβ and Copolymer 1, as therapies able to modify the disease course in relapsing-remitting and secondary progressive, as well as the available immunopathological and clinical data suggesting that the early treatment of MS with safe profile immunomodulatory drugs could be advantageous compared to late treatments, supports the 'putative' relevance of these new drugs in the early treatment of MS patients. However we must wait for the results of ongoing clinical trials to define if such an early treatment has substantial advantages compared to late treatment.

KW - Copolymer 1

KW - Early treatment

KW - IFNβ

KW - Immunomodulatory drugs

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0034674196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034674196&partnerID=8YFLogxK

M3 - Articolo

C2 - 10935262

AN - SCOPUS:0034674196

VL - 30

SP - 1265

EP - 1268

JO - Revista de Neurologia

JF - Revista de Neurologia

SN - 0210-0010

IS - 12

ER -